Harnessing Oncolytic Virus-mediated Anti-tumour Immunity
Treatment of permissive tumours with the oncolytic virus (OV) VSV-Δ51 leads to a robust anti-tumour T cell response, which contributes to efficacy; however, many tumours are not permissive to in vivo treatment with VSV-Δ51. In an attempt to channel the immune stimulatory properties of VSV-Δ51 and br...
| Main Author: | |
|---|---|
| Language: | en |
| Published: |
2012
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/23318 |